Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Sutro Biopharma, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 116
- −2 vs. Q4 2022
- Shares held
- 53.5M
- +3.54M (+7.1%) vs. Q4 2022
- Total value
- $247.5M
- −$156.1M (−38.7%) vs. Q4 2022
- New holders
- 18
- 50 more added
- Sold out
- 20
- 30 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting STRO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 100 | $545.7M |
| Q1 2026 | 78 | $358.3M |
| Q4 2025 | 63 | $64.8M |
| Q3 2025 | 88 | $46.4M |
| Q2 2025 | 101 | $39.6M |
| Q1 2025 | 113 | $40.0M |
| Q4 2024 | 123 | $117.6M |
| Q3 2024 | 130 | $216.4M |
| Q2 2024 | 119 | $185.1M |
| Q1 2024 | 117 | $301.7M |
| Q4 2023 | 114 | $238.7M |
| Q3 2023 | 109 | $194.3M |
| Q2 2023 | 120 | $251.6M |
| Q1 2023 | 116 | $247.5M |
| Q4 2022 | 119 | $403.7M |
| Q3 2022 | 113 | $279.6M |
| Q2 2022 | 115 | $240.9M |
| Q1 2022 | 114 | $342.2M |
| Q4 2021 | 117 | $593.2M |
| Q3 2021 | 120 | $752.5M |
| Q2 2021 | 124 | $766.7M |
| Q1 2021 | 138 | $1.01B |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Sutro Biopharma, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Parkman Healthcare Partners LLC | 1,100,038 | $5.08M | 1.11% | +234,063+27.0% | Added |
| Verition Fund Management LLC | 1,145,786 | $5.29M | 0.08% | −458,443−28.6% | Reduced |
| Dimensional Fund Advisors LP | 1,173,199 | $5.42M | 0.00% | +505,656+75.7% | Added |
| Goldman Sachs Group Inc | 1,500,613 | $6.93M | 0.00% | +423,145+39.3% | Added |
| Samsara BioCapital, LLC | 1,675,579 | $7.74M | 1.60% | 00.0% | Unchanged |
| Candriam Luxembourg S.C.A. | 1,860,775 | $7.91M | 0.05% | +1,071,591+135.8% | Added |
| Frazier Life Sciences Management, L.P. | 1,776,479 | $8.21M | 0.59% | 00.0% | Unchanged |
| Baillie Gifford & Co | 1,867,654 | $8.63M | 0.01% | −961−0.1% | Reduced |
| Holocene Advisors, LP | 2,132,873 | $9.85M | 0.05% | −180,669−7.8% | Reduced |
| Vanguard Group Inc | 2,776,962 | $12.8M | 0.00% | +132,290+5.0% | Added |
| Franklin Resources Inc | 2,837,869 | $13.1M | 0.01% | −2660.0% | Reduced |
| State Street Corp | 2,922,712 | $13.5M | 0.00% | +1,071,427+57.9% | Added |
| BVF Inc | 3,347,946 | $15.5M | 0.57% | 00.0% | Unchanged |
| Rubric Capital Management LP | 4,360,487 | $20.1M | 0.80% | +1,148,615+35.8% | Added |
| BlackRock Inc. | 5,020,823 | $23.2M | 0.00% | +160,683+3.3% | Added |
| Suvretta Capital Management, LLC | 5,689,086 | $26.3M | 1.27% | +123,987+2.2% | Added |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −790,600−100.0% | Sold out |
| Endurant Capital Management LP | 0 | $0 | 0.00% | −281,895−100.0% | Sold out |
| Caas Capital Management LP | 0 | $0 | 0.00% | −115,981−100.0% | Sold out |
| New York Life Investment Management LLC | 0 | $0 | 0.00% | −69,012−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −65,227−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −42,600−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −32,058−100.0% | Sold out |
| Pura Vida Investments, LLC | 0 | $0 | 0.00% | −31,409−100.0% | Sold out |
| Delphia (USA) Inc. | 0 | $0 | 0.00% | −29,456−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −20,300−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −18,060−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −17,610−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −17,553−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −15,868−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −15,567−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −14,712−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −41−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −33−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −93−100.0% | Sold out |
| Personal Capital Advisors Corp | – | – | – | – | Not filed |